Trials / Completed
CompletedNCT04256473
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Erasmus Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV infusion of mutant pro-urokinase against usual treatment with IV alteplase in patients presenting with ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mutant pro-urokinase | Intravenous administration |
| DRUG | Alteplase | Intravenous administration |
Timeline
- Start date
- 2019-08-10
- Primary completion
- 2022-03-26
- Completion
- 2022-05-26
- First posted
- 2020-02-05
- Last updated
- 2023-09-07
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04256473. Inclusion in this directory is not an endorsement.